This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Epitinib

Hutchison MediPharma Limited

Drug Names(s): HMPL-813

Description: Epitinib (HMPL-813) is a novel small molecule compound that targets Epidermal Growth Factor Receptor (EGFR). In preclinical studies, it reduced survival of EGFR high expression tumor cells by inhibiting EGFR signaling pathway and induced cell cycle arrest and apoptosis. Epitinib also demonstrated a broad anti-tumor spectrum via oral dosing in multiple xenographs such as non-small cell lung carcinoma HCC827, human epidermoid cancer A-431, nasopharyngeal cancer Fadu and some brain tumors.


Epitinib News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug